ArticleJournal of surgical oncology2019
Preclinical imaging of epidermal growth factor receptor with ABY-029 in soft-tissue sarcoma for fluorescence-guided surgery and tumor detection.
Article in Journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- Epidermal Growth Factor Receptor-Targeted Fluorescence Molecular Imaging for Postoperative Lymph Node Assessment in Patients with Oral Cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Trial
- Review
- First-in-Human Study of ABY-029, a Novel Fluorescent Peptide that Targets EGFR, Applied to Soft-Tissue Sarcomas.Molecular cancer therapeutics · 2025Article
- Novel GAL7-targeted fluorescent molecular imaging probe for high-grade squamous intraepithelial lesion and cervical cancer screening.EJNMMI research · 2025Article
- Democratizing advanced surgical guidance: decoupling the state-of-the-art from tertiary centers and breaking trail for autonomous robotic surgery in austere environments.Proceedings of SPIE--the International Society for Optical Engineering · 2025Article
- Two-color fluorescence-guided surgery for head and neck cancer resections.Journal of biomedical optics · 2025Article
- Tumor-selective dye-based histological electrophoresis enables intraoperative tumor diagnosis via tumor-specific enhancement.Theranostics · 2025Article
- Perspective on the use of fluorescence molecular imaging for peripheral and deepJournal of biomedical optics · 2025Review
- A simplified fluorescence assay to estimate binding on- and off-rates for molecular targeted imaging agents.Proceedings of SPIE--the International Society for Optical Engineering · 2025Article
- In Vivo Labeling and Detection of Circulating Tumor Cells in Mice Using OTL38.Molecular imaging and biology · 2024Article
- Neoadjuvant Therapies Do Not Reduce Epidermal Growth Factor Receptor (EGFR) Expression or EGFR-Targeted Fluorescence in a Murine Model of Soft-Tissue Sarcomas.Molecular imaging and biology · 2024Article
- Fluorescence guidance improves the accuracy of radiological imaging-guided surgical navigation.Journal of surgical oncology · 2023Article
- Improved Discrimination of Tumors with Low and Heterogeneous EGFR Expression in Fluorescence-Guided Surgery Through Paired-Agent Protocols.Molecular imaging and biology · 2023Article
- Current and Future Applications of Fluorescence Guidance in Orthopaedic Surgery.Molecular imaging and biology · 2023Review
- Intraoperative Evaluation of Soft Tissue Sarcoma Surgical Margins with Indocyanine Green Fluorescence Imaging.Cancers · 2023Article
- Safety assessment of fluorescently labeled anti-EGFR Nanobodies in healthy dogs.Frontiers in pharmacology · 2023Article
- Paired-agent imaging as a rapidFrontiers in oncology · 2023Article
- Protein scaffolds: antibody alternatives for cancer diagnosis and therapy.RSC chemical biology · 2022Review
- Assessment and Comparison of Three Dimensional Exoscopes for Near-Infrared Fluorescence-Guided Surgery Using Second-Window Indocyanine-Green.Journal of Korean Neurosurgical Society · 2022Article
- First Clinical Results of Fluorescence Lifetime-enhanced Tumor Imaging Using Receptor-targeted Fluorescent Probes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
BACKGROUND AND
objectivesFluorescence-guided surgery using epidermal growth factor receptor (EGFR) targeting has been performed successfully in clinical trials using a variety of fluorescent agents. We investigate ABY-029 (anti-EGFR Affibody
methodsFive xenograft soft-tissue sarcoma cell lines were implanted into immunosuppressed mice. ABY-029 and IRDye 700DX were each administered at 4.98 μM. Fluorescence from in vivo and ex vivo (fresh and formalin-fixed) fixed tissues were compared. The performance of three fluorescence imaging systems was assessed for ex vivo tissues.
resultsABY-029 is retained longer within tumor tissue and achieves higher tumor-to-background ratios both in vivo and ex vivo than IRDye 700DX. ABY-029 fluorescence is less susceptible to formalin fixation than IRDye 700DX, but both agents have disproportional signal loss in a variety of tissues. The Pearl Impulse provides the highest contrast-to-noise ratio, but all systems have individual advantages.
conclusionsABY-029 demonstrates promise to assist in wide local excision of soft-tissue sarcomas. Further clinical evaluation of in situ or freshly excised ex vivo tissues using fluorescence imaging systems is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.